Psychedelic Drugs

A single high dose of psilocybin can cause lasting physical changes in the human brain. Scientists found that temporary increases in brain randomness during the experience predict improved well-being and mental flexibility for at least a month.

A single dose of psilocybin paired with behavioral therapy proved remarkably effective at helping cigarette smokers quit. A new clinical trial shows the psychedelic intervention substantially outperformed standard nicotine patches over a six-month tracking period.

A new clinical trial suggests that repeated doses of psilocybin can safely reduce symptoms of obsessive-compulsive disorder. The findings provide evidence that multiple weekly treatments offer lasting relief for those struggling with traditional therapies.

A quick scan of your resting brain waves might hold the secret to predicting how intensely you will react to psilocybin, offering doctors a potential new tool for personalizing psychedelic therapy.

Women who use psychedelics to cope with sexual trauma report increased emotional intimacy during sex, but these perceived benefits vary widely based on gender and personal history, according to a recent analysis of global drug users.

A new study suggests the hallucinogen DMT might improve upon existing rapid treatments for severe depression. The research shows a single dose of DMT provides sustained relief from both depressive and anxiety-like symptoms in mice.

Recent research is dampening the hype around psychedelic therapy. By adjusting for how clinical trials are designed, scientists found that drugs like LSD and psilocybin offer similar depression relief to traditional antidepressants, rather than vastly superior results.

A double-blind trial suggests that microdosing the psychedelic drug LSD can reverse blunted neurological responses to emotional rewards, potentially offering targeted biological interventions for individuals struggling with mild to moderate depression.

Individuals with a history of severe childhood trauma who attended ceremonial psychedelic retreats reported marked reductions in anxiety and increased well-being. The findings suggest psychedelics could offer a novel approach for populations historically resistant to traditional mental health therapies.

A new analysis reveals that psilocybin temporarily slows down human reaction times and mildly impairs executive functions. The findings highlight the need for safety protocols as psychedelic therapies move closer to widespread clinical acceptance.

A recent trial involving healthy volunteers demonstrates that a single dose of psilocybin can prompt lasting changes in personal values, increasing self-acceptance and appreciation for life through acute feelings of spiritual euphoria and profound unity.

New findings published in Nature Medicine indicate that a brief dose of the psychedelic DMT, administered with dedicated psychological support, safely and rapidly relieves major depression. These mental health improvements tend to last for up to three months.

A new clinical trial directly compares MDMA with its chemical relative MDA for the first time. The results reveal how slight molecular differences can dramatically alter the duration, visual intensity, and adverse effects of psychoactive drugs.

A placebo-controlled experiment reveals how psilocybin changes human time perception. By testing volunteers on a visual timing task, researchers found the psychedelic compound causes people to underestimate durations and feel time passing much slower than normal.

Sporadic recreational use of magic mushrooms and LSD does not damage memory or attention, a new study finds. Instead, young adults who occasionally use classic psychedelics display a distinct advantage in shifting problem-solving strategies and adapting to new rules.